Workflow
超微创技术
icon
Search documents
破解老年排尿困难,超微创技术打通“生命通道”
Xin Lang Cai Jing· 2026-01-06 19:29
65岁的张爷爷,最近被小便问题困扰得不轻。夜尿频繁,每晚要起夜十多次,严重影响睡眠质量。百般 无奈之下,张爷爷找到了江苏省省级机关医院泌尿外科张世革主任。 (来源:新华日报) □ 本报记者 杨 彦 尿频、尿不尽、夜尿频繁……这些看似寻常的排尿问题,却成为困扰众多老年人的"难言之隐"。随着人 口老龄化加剧,老年排尿障碍的发病率逐年攀升,严重影响老年人的生活质量。本期《跟着名家学健 康》,邀请到江苏省省级机关医院泌尿外科张世革主任,他将为大家详解老年排尿障碍的成因、前沿治 疗技术及健康防护要点,带大家走出诊疗误区。 "隧道"变窄,老年人群容易遭遇排尿困难 江苏省省级机关医院作为老年病专科医院,接诊的高龄患者很多。与传统手术需全身或半身麻醉不同, 超微创技术可在局部麻醉下完成,有效降低了心脏病、呼吸道疾病等高龄患者的手术风险,让许多原本 只能依赖导尿管生活的老人重获正常排尿能力。该院接受手术最高龄患者,已经超过了百岁。对于50 岁左右就出现严重排尿障碍,或60岁左右仍有较多社会活动、对生活质量要求较高的患者,若药物治疗 效果不佳且不愿接受传统切割手术,超微创技术也是理想选择。 "老年人群遭遇排尿困难,主要有三个原因 ...
每周股票复盘:天臣医疗(688013)布局5mm超微创手术机器人
Sou Hu Cai Jing· 2025-09-20 18:42
Core Viewpoint - Tianchen Medical (688013) has established a dual-engine strategy focusing on minimally invasive capabilities driven by end-execution components and an intelligent surgical robot ecosystem supported by the M platform, with a focus on 5mm ultra-minimally invasive technology and smart electric surgical robots [1][3]. Group 1: Company Performance - As of September 19, 2025, Tianchen Medical's stock closed at 62.16 yuan, down 7.57% from the previous week [1]. - The company's current total market capitalization is 5.045 billion yuan, ranking 71st out of 126 in the medical device sector and 3263rd out of 5153 in the A-share market [1]. Group 2: Research and Development - R&D expenses accounted for 12.10% of revenue, with 53 new authorizations, including 44 core technology invention patents [2][4]. - The M platform and I exploration of the intelligent surgical platform project have entered the design verification stage, focusing on intraoperative image recognition, operational assistance, and data analysis [1][4]. Group 3: International and Domestic Business Development - The company is pursuing a dual-drive strategy for domestic and overseas markets, with overseas revenue of 53.4701 million yuan, accounting for 34.24% of total revenue, and products covering 64 countries and regions [3][4]. - In the domestic market, the company emphasizes "clinical quality first + reasonable pricing" to ensure the supply and quality of centralized procurement products while promoting market access, product iteration, and channel penetration [3].